Compare MPLX LP (MPLX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Sanofi SA — how do they compare? MPLX LP trades at $56.64 (market cap $57.97B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.54%). Which is the better fit depends on your goals.
| MPLX | SNY | |
|---|---|---|
Market Cap | $57.97B | $104.83B |
Sector | Technology | Health |
52-Week High | $59.17 | $52.34 |
52-Week Low | $47.80 | $41.33 |
Enterprise Value | $82.60B | $121.32B |
Dividend Yield | 7.54% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $57.13, showing modest daily gains of 0.12%. The stock maintains a bullish technical outlook with strong moving average signals, while fundamentals reveal robust profitability with 41.24% net margins and consistent earnings beats in recent quarters. Recent news highlights the company's resilient midstream business model and attractive dividend yield, with analyst consensus strongly favoring the stock.
Outlook remains positive given the 71% buy rating consensus and $60 price target representing 5% upside. Key risks include energy market volatility and the Q1 2026 earnings miss, but the company's fee-based contracts and Permian Basin exposure provide stability. The sustainable dividend and strong cash flow generation support long-term value for income-focused investors.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
